Today: GB Sciences' Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by Dr. Dominick Monaco at Cannabis Conference 2019, As Featured on Cover of Cannabis Business Times
LAS VEGAS, April 2, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announced that Dr. Dominick Monaco, GB Sciences' Director of Medical Formulations, will be a featured speaker at the Las Vegas Cannabis Conference TODAY, April 2, at 4:40pm. He will be discussing "Science That Sells: Debunking the Sativa, Indica Myths & Instead Focusing on Terpenoids, Cannabinoids and Flavonoids." Presented by the Cannabis Business Times and Cannabis Dispensary, the conference will bring thousands of cannabis professionals across the country to Las Vegas. Learn more here.
GB Sciences is located just three miles off the Vegas strip, in a 28,000 square foot state-of-the-art facility featured on the cover of Cannabis Business Times' March 2019 issue. The article also highlights the company's groundbreaking research program, led by Dr. Andrea Small-Howard with the support of Dr. Monaco and our university research partners, who have created a patent portfolio of cannabis-based therapies that covers over 60 disease and health conditions including Parkinson's disease, neuropathic pain, and cardiac hypertrophy. Read the full article here.
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
Liz Bianco, email@example.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/today-gb-sciences-use-of-controlled-cultivation-product-formulations-and-research-will-be-presented-by-dr-dominick-monaco-at-cannabis-conference-2019-as-featured-on-cover-of-cannabis-business-times-300822531.html
SOURCE GB Sciences, Inc.
Company Codes: OTC-QB:GBLX, OTC-PINK:GBLX